Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $364.2 million.

  • Akebia Therapeutics' Liabilities and Shareholders Equity rose 75.80% to $364.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 38.69%. This contributed to the annual value of $220.7 million for FY2024, which is 8.70% down from last year.
  • Per Akebia Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $364.2 million for Q3 2025, which was up 5.37% from $345.6 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Liabilities and Shareholders Equity peaked at $628.7 million during Q1 2021, and registered a low of $207.1 million during Q3 2024.
  • Over the past 3 years, Akebia Therapeutics' median Liabilities and Shareholders Equity value was $241.7 million (recorded in 2023), while the average stood at $264.1 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Liabilities and Shareholders Equity plummeted by 52.12% in 2023, and later surged by 75.80% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Liabilities and Shareholders Equity (MRQ) stood at $529.3 million in 2021, then crashed by 32.74% to $356.1 million in 2022, then crashed by 32.12% to $241.7 million in 2023, then decreased by 8.70% to $220.7 million in 2024, then skyrocketed by 65.02% to $364.2 million in 2025.
  • Its last three reported values are $364.2 million in Q3 2025, $345.6 million for Q2 2025, and $310.2 million during Q1 2025.